Compare BBCP & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBCP | TENX |
|---|---|---|
| Founded | 1983 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 367.7M | 317.8M |
| IPO Year | 2017 | 2001 |
| Metric | BBCP | TENX |
|---|---|---|
| Price | $10.53 | $15.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $8.25 | ★ $29.67 |
| AVG Volume (30 Days) | 289.5K | ★ 1.4M |
| Earning Date | 06-04-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $392,867,000.00 | N/A |
| Revenue This Year | $4.90 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.56 | $5.77 |
| 52 Week High | $12.19 | $19.40 |
| Indicator | BBCP | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 49.10 | 58.40 |
| Support Level | $10.39 | $12.84 |
| Resistance Level | $12.08 | $16.35 |
| Average True Range (ATR) | 0.49 | 1.28 |
| MACD | -0.21 | -0.07 |
| Stochastic Oscillator | 7.78 | 48.37 |
Concrete Pumping Holdings Inc is a provider of concrete pumping services and concrete waste management services in the fragmented United States and United Kingdom markets. Its large fleet of specialized pumping equipment and trained operators enables it to deliver concrete placement solutions. The company's operating segments include U.S. Concrete Pumping, U.K. Operations, and U.S. Concrete Waste Management Services, with the majority of revenue generated from the U.S. Concrete Pumping segment. Geographically, it operates in the United States and the United Kingdom, generating majority of its revenue from the United States.
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.